Patents by Inventor Peter Van Remoortere

Peter Van Remoortere has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTION
    Publication number: 20180021361
    Abstract: A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.
    Type: Application
    Filed: July 21, 2017
    Publication date: January 25, 2018
    Applicants: JANSSEN PHARMACEUTICALS, INC., ACHILLION PHARMACEUTICALS, INC.
    Inventors: Maria Gloria Beumont, Lieve Bijnens, Lawrence M. Blatt, Sushmita Mukherjee Chanda, John Fry, Eugene Jans, Thomas Naoki Kakuda, Sivi Mahadevan, Roel Mertens, Gaston Rafael Picchio, Alex Van Dijck, Peter Van Remoortere, David Apelian, Dawei Chen, Milind Deshphande, James Hui, Avinash Phadke
  • Combination Therapy Regimen For Treatment Of Selected HCV Genotypes
    Publication number: 20180021360
    Abstract: A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6, but not genotype 3 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.
    Type: Application
    Filed: July 21, 2017
    Publication date: January 25, 2018
    Applicants: Janssen Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc.
    Inventors: Maria Gloria Beumont, Lieve Bijnens, Lawrence M. Blatt, Sushmita Mukherjee Chanda, John Fry, Eugene Jans, Thomas Naoki Kakuda, Sivi Mahadevan, Roel Mertens, Gaston Rafael Picchio, Alex Van Dijck, Peter Van Remoortere, David Apelian, Dawei Chen, Milind Deshphande, James Hui, Avinash Phadke
  • COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTION
    Publication number: 20170319572
    Abstract: A composition, including a fixed dose composition, comprising Compound (I), Compound (II), and Compound (III) for the treatment of hepatitis C, and methods of manufacture thereof.
    Type: Application
    Filed: July 25, 2017
    Publication date: November 9, 2017
    Applicants: JANSSEN PHARMACEUTICALS, INC., ACHILLION PHARMACEUTICALS, INC.
    Inventors: Maria Gloria Beumont, Lieve Bijnens, Lawrence M. Blatt, Sushmita Mukherjee Chanda, John Fry, Eugene Jans, Thomas Naoki Kakuda, Sivi Mahadevan, Roel Mertens, Gaston Rafael Picchio, Alex Van Dijck, Peter Van Remoortere, David Apelian, Dawei Chen, Milind Deshphande, James Hui, Avinash Phadke
  • COMBINATION THERAPY REGIMEN FOR TREATMENT OF HCV
    Publication number: 20170087174
    Abstract: A composition, including a fixed dose composition, comprising Compound (I), Compound (II), and Compound (III) for the treatment of hepatitis C, and methods of manufacture thereof.
    Type: Application
    Filed: September 29, 2016
    Publication date: March 30, 2017
    Inventors: Maria Gloria Beumont, Lieve Bijnens, Lawrence M. Blatt, Sushmita Mukherjee Chanda, John Fry, Eugene Jans, Thomas Naoki Kakuda, Sivi Mahadevan, Roel Mertens, Gaston Rafael Picchio, Alex Van Dijck, Peter Van Remoortere, David Apelian, Dawei Chen, Milind Deshphande, James Hui, Avinash Phadke
  • SUSTAINED RELEASE OF POORLY WATER SOLUBLE ACTIVE COMPOUNDS
    Publication number: 20120148678
    Abstract: We have disclosed an implantable sustained release composition comprising, a biocompatible, biodegradable polymer, a cyclodextrin inclusion complex of a poorly water soluble pharmaceutical agent present, and a plasticizer, where the polymer is the minority phase of the formulation. Furthermore, The we disclose an implantable sustained release composition that provides a detectable plasma level of an otherwise poorly soluble drug for at least 28 days.
    Type: Application
    Filed: December 8, 2010
    Publication date: June 14, 2012
    Applicant: Advanced Technologies and Regenerative Medicine, LLC.
    Inventors: Deborah M. Schachter, Qiang Zhang, Peter Van Remoortere, Yufu Li